Tweetorial #3: Best Practices w/ T-cell Therapy
Pre-Survey

Before you view the activity, please take this pre-assessment. Taking this pre-assessment does not immediately qualify learners to earn credit.

Certificates of credit will only be sent to learners who also receive a passing score on the post-test (separate from this survey), and fill out the evaluation form and application for credit.

Question Title

* 1. HCPs: What are your credentials?

MD/DO

Trainee/Fellow

Nurse

Pharmacist

Other (please specify)

Question Title

* 2. What is your community of practice?

Academic

Community

Other (please specify)

Question Title

* 3. What is your specialty?

Hematology

Oncology

Pathology

Radiology

Other (please specify)

Question Title

* 4. Based on an Association of Community Cancer Centers @ACCCBuzz survey conducted in 2020, which of the following challenges was most frequently cited as a barrier to treatment with bispecific antibodies?

Transitions of care

Managing remote patients

Insurance coverage

Managing adverse effects

Question Title

* 5. 74-YOM dx w/ IgG MM w/ t(11;14) here discuss tx with a bispecific ab. After explaining tx is continued until disease progression, he asks if he needs to receive tx and monitoring at an academic center. Which of the following is the best response regarding where tx is delivered?

Only academic centers

Only community practice

Only in hospital

Community and/or academic

Question Title

* 6. The director of the cancer center is exploring providing bispecific antibodies or CAR-T for multiple myeloma. Which of the following processes would need to be developed in order to provide both CAR-T and bispecific antibodies?

Leukapheresis

Adverse event counseling

Stem cell mobilization

T-cell re-engineering

Question Title

* 7. Please let us know who you are so we can connect your responses to your post-test & application to claim CME credit (completed after participating in the activity)

First & Last Name

State/Province

ZIP/Postal Code

Country

Email Address

Tweetorial #3: Best Practices w/ T-cell Therapy***Pre-Survey***

Question Title

* 1. HCPs: What are your credentials?

Question Title

* 2. What is your community of practice?

Question Title

* 3. What is your specialty?

Question Title

* 4. Based on an Association of Community Cancer Centers @ACCCBuzz survey conducted in 2020, which of the following challenges was most frequently cited as a barrier to treatment with bispecific antibodies?

Question Title

* 5. 74-YOM dx w/ IgG MM w/ t(11;14) here discuss tx with a bispecific ab. After explaining tx is continued until disease progression, he asks if he needs to receive tx and monitoring at an academic center. Which of the following is the best response regarding where tx is delivered?

Question Title

* 6. The director of the cancer center is exploring providing bispecific antibodies or CAR-T for multiple myeloma. Which of the following processes would need to be developed in order to provide both CAR-T and bispecific antibodies?

Question Title

* 7. Please let us know who you are so we can connect your responses to your post-test & application to claim CME credit (completed after participating in the activity)

Tweetorial #3: Best Practices w/ T-cell Therapy
Pre-Survey